Optimizing H. pylori management in the Middle East
H. pylori infection is a well-established disease, yet rising antimicrobial resistance and ongoing unmet needs continue to complicate its management across our region. This program supports healthcare professionals in optimizing diagnosis and treatment, with the First Regional Middle East Consensus as its key scientific reference.
Prof. Ala Sharara
Lebanon
Dr. Talal Al-Taweel
Kuwait
Dr. Ahmed Alsaegh
Bahrain
Prof. Fahad I. Alsohaibani
Saudi Arabia
Prof. Peter Malfertheiner
Germany
Dr. Ahmad Jazzar
United Arab EmiratesWelcome back
Enter your email and password to continue from where you stopped.
Expertise from across the Middle East
Five speakers from the region are joined by Prof. Peter Malfertheiner (Germany), bringing international guidance into the regional context.
Your path to CME credit
- RegisterTakes about 2 minutes
- Answer 6 knowledge questionsOne for each presentation, no grades
- Watch 6 presentationsAt your own pace, with 1 question after each
- Review your answersCorrect answers and rationale for every question
- Receive your CME certificateOnce credit is determined by the AAFP
At the conclusion of this activity, participants should be able to:
Identify the full range of indications for H. pylori testing beyond dyspepsia, including high-risk NSAID/aspirin use, long-term PPI therapy, unexplained iron-deficiency anemia, ITP or B12 deficiency, and gastric MALT lymphoma. Use age and alarm features to choose between non-invasive testing and endoscopy.
Dr. Talal Al-TaweelDescribe the bacterial, host and treatment-related drivers of H. pylori antimicrobial resistance, including the genetic mechanisms behind clarithromycin, levofloxacin and metronidazole resistance. Apply antibiotic stewardship principles when selecting therapy.
Prof. Fahad I. AlsohaibaniSummarize the regional and global epidemiology and disease burden of H. pylori, explain why H. pylori gastritis is now classified as an infectious disease that warrants treatment, and identify patients who still need endoscopic surveillance after successful eradication.
Prof. Ala ShararaApply the Middle East consensus treatment algorithm, in alignment with Maastricht VI/Florence, to select appropriate first-line, second-line and rescue eradication regimens based on local clarithromycin resistance and prior antibiotic exposure.
Prof. Peter MalfertheinerSelect the appropriate diagnostic test for the clinical question (active infection, eradication status, mucosal disease or resistance), and recognize medication effects and timing errors that cause false-negative results.
Dr. Ahmed AlsaeghDescribe the progression from chronic active gastritis to gastric adenocarcinoma, and implement a primary-care pathway that emphasizes early eradication before severe atrophy develops, along with timely referral for endoscopy.
Dr. Ahmad Jazzar
Application for CME credit has been filed with the American Academy of Family Physicians (AAFP). Determination of credit is pending.
Accreditation from the AAFP may be converted to accreditation from your local country.
This educational activity is supported by an independent educational contribution from NewBridge Pharmaceuticals.
AvailabilityContent is available for 12 months from launch, until 1 November 2027.
P&CC (Publishing and Communications Co. Ltd.), based in Larnaca, Cyprus, is a medical communications company that designs and manages accredited medical education programs for healthcare professionals across the Middle East.
www.modernmedicine.me
Privacy notice draft — to be supplied and reviewed before launch. Your registration details, answers and viewing progress are processed by P&CC to provide this activity and report participation.